NERISONE FORTE

Adults:

Initially, Nerisone Forte should be applied thinly twice daily. When the condition improves, one application daily is appropriate. It is intended for short-term use of 1-2 weeks with a usual maximum duration of 2 weeks. In view of the high efficacy and potency of Nerisone Forte, no more than 60 g a week should be applied.

Children of 5 years of age and over:

Initially, Nerisone Forte should be applied thinly twice daily. When the condition improves, one application daily is appropriate. It should be used with great care, for short periods and generally only on the advice of a doctor specialising in dermatology.

Courses should be limited to 1-2 weeks. Nerisone Forte should not be used in children under 5 years of age. 4).

Elderly:

Natural thinning of the skin occurs in the elderly. No special precautions are required, however, when Nerisone Forte is used in this group of patients. Nerisone Forte Ointment is suitable for very dry skin conditions. It has an anhydrous fatty base.

Its occlusive effect promotes the healing process.

Common local adverse reactions reported with Nerisone formulations in clinical studies include burning, pruritus, erythema and irritations. In common with all potent topical corticosteroids, there may be local signs such as atrophy of the skin, striae, thinning, acneform changes, hypertrichosis and systemic effects of the corticoid due to absorption and telangiectasia, particularly in skin folds and where occlusive dressings are used.

Side-effects may occur when Nerisone Forte is applied to large areas of the body (10% or more) and for long periods of time (more than 10 days). Systemic absorption can produce the features of hypercorticism. In rare cases, allergic skin reactions may occur.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

Long-term continuous therapy with topical corticosteroids should be avoided, irrespective of age. Adrenal suppression can occur, even without occlusion. In view of the high efficacy and potency of Nerisone Forte it is suggested that treatment for one or two weeks should generally be sufficient to obtain control of even the most refractory lesion, after which a change to Nerisone can usually be made if further therapy is necessary.

Since prolonged therapy with potent topical corticosteroids may cause local atrophic changes such as striae, thinning, hypertrichosis and telangiectasia, particularly in skin folds and where occlusive dressings are used, it is recommended that the progress of patients under treatment for more than one week with Nerisone Forte be reviewed weekly, and that repeat prescriptions be written only when the prescribing physician has seen the patient again.

Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses following development of tolerance, risk of generalised pustular psoriasis, and local and systemic toxicity due to impaired barrier function of the skin.

Careful patient supervision is important in psoriasis. Since absorption is increased with the use of occlusive dressings, these should not be left on for more than 24 hours. If secondary infection occurs during treatment, the use of occlusive dressings should be stopped until the infection has been eliminated, and appropriate treatment of the infection should be instituted if it persists.

Exacerbation of skin infections may occur. Infections or secondarily infected dermatoses require additional therapy with antibiotics or chemotherapeutic agents. This treatment can often be topical, but for heavy infections systemic antibacterial therapy may be necessary.

If fungal infections are present, a topically active antimycotic should be applied. If aggravation of skin irritation develops with the use of Nerisone, treatment should be withdrawn and appropriate therapy installed. Allergic contact dermatitis due to topical corticosteroids and excipients can occur.

Acne vulgaris, undiagnosed perianal and genital pruritus, napkin eruptions, viral infections, primary bacterial or fungal infections of the skin.
- Post-vaccination skin reactions in the area to be treated. Nerisone Forte is not suitable for the treatment of ophthalmic conditions.

Infants and children up to the age of 4 years must not be treated with Nerisone Forte. Nerisone Forte Ointment should never be applied to the face. Hypersensitivity to the active substances or to any of the excipients.